EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Resistance to anti-HER2 therapies in breast cancer remains a significant clinical challenge. Here, the authors demonstrate that EZH2 regulates response to HER2-targeting therapies in breast cancer, in part, by modulating the expression of PPP2R2B.
Saved in:
Main Authors: | Yi Bao, Gokce Oguz, Wee Chyan Lee, Puay Leng Lee, Kakaly Ghosh, Jiayao Li, Panpan Wang, Peter E. Lobie, Sidse Ehmsen, Henrik J. Ditzel, Andrea Wong, Ern Yu Tan, Soo Chin Lee, Qiang Yu |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/d3c09063233a46f7b4d0dbd7cf8055f0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Asxl1 deficiency in embryonic fibroblasts leads to cellular senescence via impairment of the AKT-E2F pathway and Ezh2 inactivation
by: Hye Sook Youn, et al.
Published: (2017) -
Interplay of DNA methyltransferase 1 and EZH2 through inactivation of Stat3 contributes to β-elemene-inhibited growth of nasopharyngeal carcinoma cells
by: JingJing Wu, et al.
Published: (2017) -
EZH1 and EZH2 promote skeletal growth by repressing inhibitors of chondrocyte proliferation and hypertrophy
by: Julian C. Lui, et al.
Published: (2016) -
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
by: Avisek Majumder, et al.
Published: (2021) -
Evidence of the Involvement of Spinal EZH2 in the Development of Bone Cancer Pain in Rats
by: Chen H, et al.
Published: (2021)